Zorro Trades
Small-cap, research analyst, long-term horizon

A Small Cap Pharmaceutical That Is Making Money: Why Tianyin Is Severely Undervalued

Almost all pharmaceutical companies that I stumble upon have similar characteristics. These characteristics include having some blockbuster drug in the pipeline surrounded by much hype and promise, receiving minimal revenues stemming from a different product that has less potential than the pipeline drug, consistently losing money and burning cash on research and development, and only having enough cash to fund operations until around the date when results of their blockbuster drug are expected to be released. In other words, the company's stock price and valuation is hanging on the passing of the pipeline drug, and can either be a homerun or a strike out. It's a hit or miss.

Tianyvin (NYSEMKT:TPI) is the exact opposite. This Chinese pharmaceutical...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details